The treatments combine monoclonal antibodies (mAbs) alongside potent anti-cancer agents, often a small molecule drug, combined through a chemical linker ... year shares in Mersana Therapeutics ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed last Friday at $0.75. Leverage the ...

Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...

CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Chainlink could reach a maximum value of $32.94 in 2025. By 2028, LINK could reach a maximum price of $102.75. In 2031, Chainlink will range between $256.84 to $319.36. Chainlink (LINK) emerged as a ...

We also provide Docker images which has macOS SDK pre-installed in addition to cargo-zigbuild and Rust, for example to build for x86_64 macOS: Version 2.32 can be specified, but runs on a host with ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen ...

Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with ...

Pre-Market: 5:02:04 a.m. EST Loading Chart for MRSN ...

After hours: February 13 at 4:10:10 PM EST Loading Chart for CDLX ...